From the Center for Clinical Pharmacology, Departments of Medicine
(R.K.D., D.G.G.) and Pharmacology (E.K.J.), University of Pittsburgh Medical
Center (Pa).
Correspondence to Dr Raghvendra K. Dubey, Center for Clinical Pharmacology, Department of Medicine, 623 Scaife Hall, 200 Lothrop St, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2582. E-mail dubey{at}novell2.dept-med.pitt.edu
AbstractThe objective of this study
was to characterize the effects of exogenous and endogenous
(cardiac fibroblast-derived) adenosine on
[3H]proline and [3H]leucine incorporation,
which are reliable markers of collagen and total protein synthesis,
respectively, in rat left ventricular cardiac fibroblasts.
Growth-arrested confluent cardiac fibroblast monolayers were stimulated
with 2.5% fetal calf serum (FCS) in the presence and absence of
adenosine, 2-chloroadenosine (stable adenosine
analogue), or modulators of adenosine levels including (1)
erythro-9-(2-hydroxy-3-nonyl) adenine (adenosine deaminase
inhibitor), (2) dipyridamole
(adenosine transport blocker), and (3) iodotubericidin
(adenosine kinase inhibitor). All agents inhibited
in a concentration-dependent fashion FCS-induced
[3H]proline and [3H]leucine incorporation.
These effects were blocked by KF17837 (selective A2
antagonist) and
1,3-dipropyl-8-(p-sulfophenyl)xanthine
(A1/A2 receptor antagonist) but not
by 8-cyclopentyl-1,3-dipropylxanthine (selective A1
antagonist), thus excluding the participation of
A1 receptors. The lack of effect of CGS21680 (selective
A2A agonist) excluded involvement of A2A
receptors, thus suggesting a major role for A2B receptors.
Comparisons of the inhibitory potencies of
N6-cyclopentyladenosine (selective
A1 agonist),
5'-N-ethylcarboxamidoadenosine
(A1/A2 agonist), and
5'-N-methylcarboxamidoadenosine
(A1/A2 agonist) were consistent with
that of an A2B receptor subtype mediating the
inhibitory effects. We conclude that adenosine
inhibits FCS-induced collagen and total protein synthesis in cardiac
fibroblasts via activation of A2B receptors. These studies
suggest, but do not prove, that endogenous
adenosine may protect against cardiac fibrosis.
© 1998 American Heart Association, Inc.
Scientific Contributions
Adenosine Inhibits Collagen and Protein Synthesis in Cardiac Fibroblasts
Role of A2B Receptors
Key Words: adenosine fibroblasts myocardial infarction extracellular matrix collagen hypertrophy
This article has been cited by other articles:
![]() |
S. A. Epperson, L. L. Brunton, I. Ramirez-Sanchez, and F. Villarreal Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1171 - C1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Villarreal, S. A. Epperson, I. Ramirez-Sanchez, K. G. Yamazaki, and L. L. Brunton Regulation of cardiac fibroblast collagen synthesis by adenosine: roles for Epac and PI3K Am J Physiol Cell Physiol, May 1, 2009; 296(5): C1178 - C1184. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Katebi, M. Soleimani, and B. N. Cronstein Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development J. Leukoc. Biol., March 1, 2009; 85(3): 438 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cai, F.-F. Yi, L. Yang, D.-F. Shen, Q. Yang, A. Li, A. K. Ghosh, Z.-Y. Bian, L. Yan, Q.-Z. Tang, et al. Targeted Expression of Receptor-Associated Late Transducer Inhibits Maladaptive Hypertrophy via Blocking Epidermal Growth Factor Receptor Signaling Hypertension, March 1, 2009; 53(3): 539 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, J. Fassett, X. Hu, G. Zhu, Z. Lu, Y. Li, J. Schnermann, R. J. Bache, and Y. Chen Ecto-5'-Nucleotidase Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction Hypertension, June 1, 2008; 51(6): 1557 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, J. Pang, H. Yin, M. Li, W. Hao, C. Chen, and J.-M. Cao Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2952 - H2958. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Swaney, H. H. Patel, U. Yokoyama, N. C. Lai, M. Spellman, P. A. Insel, and D. M. Roth Adenylyl cyclase activity and function are decreased in rat cardiac fibroblasts after myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3216 - H3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wakeno, T. Minamino, O. Seguchi, H. Okazaki, O. Tsukamoto, K.-i. Okada, A. Hirata, M. Fujita, H. Asanuma, J. Kim, et al. Long-Term Stimulation of Adenosine A2b Receptors Begun After Myocardial Infarction Prevents Cardiac Remodeling in Rats Circulation, October 31, 2006; 114(18): 1923 - 1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Podgorska, K. Kocbuch, M. Grden, A. Szutowicz, and T. Pawelczyk Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to altered expression of nucleoside transporters J. Physiol., October 1, 2006; 576(1): 179 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Callera, A. C. I. Montezano, A. Yogi, R. C. Tostes, Y. He, E. L. Schiffrin, and R. M. Touyz c-Src-Dependent Nongenomic Signaling Responses to Aldosterone Are Increased in Vascular Myocytes From Spontaneously Hypertensive Rats Hypertension, October 1, 2005; 46(4): 1032 - 1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Willems, K. J. Ashton, and J. P. Headrick Adenosine-mediated cardioprotection in the aging myocardium Cardiovasc Res, May 1, 2005; 66(2): 245 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Callera, R. M. Touyz, R. C. Tostes, A. Yogi, Y. He, S. Malkinson, and E. L. Schiffrin Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-Src Hypertension, April 1, 2005; 45(4): 773 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Reichelt, L. Willems, J. G. Molina, C.-X. Sun, J. C. Noble, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick Genetic Deletion of the A1 Adenosine Receptor Limits Myocardial Ischemic Tolerance Circ. Res., February 18, 2005; 96(3): 363 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Swaney, D. M. Roth, E. R. Olson, J. E. Naugle, J. G. Meszaros, and P. A. Insel Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase PNAS, January 11, 2005; 102(2): 437 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Asbun, A. M. Manso, and F. J. Villarreal Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H227 - H234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, S. Epperson, L. Makhsudova, B. Ito, J. Suarez, W. Dillmann, and F. Villarreal Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2478 - H2486. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, J. Chen, D. Li, X. Zhang, and J. L. Mehta Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts: Modulation by PPAR-{gamma} Ligand Pioglitazone Hypertension, November 1, 2004; 44(5): 655 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, R. S. Ostrom, and P. A. Insel cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1089 - C1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tzanidis, R. D. Hannan, W. G. Thomas, D. Onan, D. J. Autelitano, F. See, D. J. Kelly, R. E. Gilbert, and H. Krum Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy Circ. Res., August 8, 2003; 93(3): 246 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Ostrom, J. E. Naugle, M. Hase, C. Gregorian, J. S. Swaney, P. A. Insel, L. L. Brunton, and J. G. Meszaros Angiotensin II Enhances Adenylyl Cyclase Signaling via Ca2+/Calmodulin: Gq-Gs CROSS-TALK REGULATES COLLAGEN PRODUCTION IN CARDIAC FIBROBLASTS J. Biol. Chem., June 27, 2003; 278(27): 24461 - 24468. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Jackson, C. Zhu, and S. P. Tofovic Expression of adenosine receptors in the preglomerular microcirculation Am J Physiol Renal Physiol, July 1, 2002; 283(1): F41 - F51. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Jackson and R. K. Dubey Role of the extracellular cAMP-adenosine pathway in renal physiology Am J Physiol Renal Physiol, October 1, 2001; 281(4): F597 - F612. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Touyz, G. He, M. El Mabrouk, and E. L. Schiffrin p38 MAP Kinase Regulates Vascular Smooth Muscle Cell Collagen Synthesis by Angiotensin II in SHR But Not in WKY Hypertension, February 1, 2001; 37(2): 574 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Dubey, D. G. Gillespie, L. C. Zacharia, Z. Mi, and E. K. Jackson A2B Receptors Mediate the Antimitogenic Effects of Adenosine in Cardiac Fibroblasts Hypertension, February 1, 2001; 37(2): 716 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Forman, J. V. Vitola, C. E. Velasco, J. J. Murray, R. K. Dubey, and E. K. Jackson Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoattractant Response J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 929 - 938. [Abstract] [Full Text] |
||||
![]() |
J. A. Auchampach and R. Bolli Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1113 - H1116. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |